Diabetes therapy trials with inhaled insulin

Area of Science:

• Pulmonary Drug Delivery
• Pharmacology
• Diabetes Management

Background:

• Insulin administration via inhalation was first explored over 50 years ago, but lacked effective delivery systems and formulations.
• Patient and provider reluctance to initiate insulin therapy, desire to reduce injections, and focus on glycemic control drive innovation in insulin delivery.
• The deep lung's large surface area (>100 m2) presents an accessible site for pulmonary drug delivery.

Purpose of the Study:

• To review four mid- to late-phase pulmonary insulin programs utilizing modern inhalation devices.
• To compare different delivery systems, insulin formulations, and their resulting bioavailability, pharmacokinetic, and glucodynamic profiles.
• To evaluate the safety and efficacy of inhaled insulin compared to subcutaneous injections.

Main Methods:

• Review of four distinct pulmonary insulin development programs.
• Analysis of various inhalation devices and insulin formulations.
• Assessment of bioavailability, pharmacokinetic, and glucodynamic data, alongside adverse event reporting.

Main Results:

• All reviewed systems successfully delivered insulin to the deep lung.
• Biological effectiveness of inhaled insulin was comparable to subcutaneous injections.
• The programs varied in delivery systems, formulations, and specific outcomes.

Conclusions:

• Modern pulmonary delivery systems enable effective inhaled insulin administration.
• Inhaled insulin provides a promising alternative to injections for diabetes management.
• Further research and development in delivery systems and formulations are ongoing.